Miraflores, Peru Clinical Trials

A listing of Miraflores, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 95 clinical trials
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

percutaneous coronary intervention
myocardial infarction
stemi
acute coronary syndrome
infarct
6040017 - Clinica El Golf
 (1.0 away) Contact site
  • 1131 views
  • 15 Sep, 2021
  • +3432 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

chemoradiotherapy
olaparib
stage iv non-small cell lung cancer
carboplatin
etoposide
Clinica Ricardo Palma Instituto de Oncologia y Radioterapia ( Site 0606)
 (1.5 away) Contact site
  • 51 views
  • 12 Sep, 2021
  • +191 other locations
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in reducing the frequency of cough-induced SUI …

chest radiograph
unexplained chronic cough
refractory chronic cough
gefapixant
Clinica Ricardo Palma ( Site 0601)
 (1.5 away) Contact site
  • 88 views
  • 15 Sep, 2021
  • +89 other locations
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

The purpose of this extension study is to establish efficacy and safety of ligelizumab. This will be assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who have completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite standard of care H1-antihistamine (H1-AH) treatment. …

urticaria
ligelizumab
antihistamines
Novartis Investigative Site
 (3.5 away) Contact site
  • 1 views
  • 29 Aug, 2021
  • +229 other locations
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).

mechanical ventilation
SARS
covid-19
chest x-ray
fever
Hospital Arzobispo Loayza
 (4.4 away) Contact site
  • 122 views
  • 17 Mar, 2021
  • +32 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

Research Site
 (1.6 away) Contact site
  • 111 views
  • 15 Sep, 2021
  • +290 other locations
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

This study will evaluate the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT is given with isoniazid (INH) daily for 4 weeks (1HP) as part of treatment for latent TB infection (LTBI) in HIV-1 and LTBI co-infected individuals.

dolutegravir
hiv-1 rna measurement
skin test
immune globulin
antiretroviral therapy
Barranco CRS
 (3.4 away) Contact site
  • 0 views
  • 30 Aug, 2021
  • +10 other locations
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.

linezolid
pulmonary tuberculosis
delamanid
clofazimine
bedaquiline
Socios En Salud
 (4.5 away) Contact site
  • 94 views
  • 15 Sep, 2021
  • +5 other locations
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue …

Instituto de Oncolog a y Radioterapia de la Cl nica Ricardo
 (1.0 away) Contact site
  • 0 views
  • 04 Sep, 2021
  • +302 other locations
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants <2 years of age with invasive fungal infection (IFI).

Instituto Nacional de Enfermedades Neoplasicas ( Site 1601)
 (2.5 away) Contact site
  • 0 views
  • 04 Sep, 2021
  • +12 other locations